(© zinkevych - stock.adobe.com)
In a nutshell
- Common wearable devices like Apple Watches and Fitbits can detect signs of inflammatory bowel disease (IBD) flares up to seven weeks before symptoms appear, potentially transforming how patients manage their condition
- The devices can differentiate between true inflammatory flares and symptom-only flares by detecting subtle changes in heart rate patterns and other physiological measurements, helping healthcare providers make more informed treatment decisions
- This research suggests that everyday consumer devices could serve as sophisticated medical monitors, opening possibilities for similar early-warning applications in other chronic inflammatory conditions
NEW YORK — Smartwatches and fitness trackers may be doing much more than counting steps and tracking workouts—they could be predicting serious medical events. A study spanning 36 states demonstrates how these common devices can detect early warning signs of inflammatory bowel disease flares, potentially revolutionizing how this chronic condition is monitored and treated.
Scientists at Mount Sinai Hospital have discovered that the physiological data collected by these everyday devices can identify patterns indicating imminent IBD flares, potentially giving patients and healthcare providers crucial advance notice for treatment adjustments. This finding could transform care for the 2.4 million Americans managing this challenging chronic condition.
IBD, which includes both Crohn’s disease and ulcerative colitis, affects the digestive tract and can cause severe inflammation, abdominal pain, and other debilitating symptoms. Current monitoring methods rely heavily on invasive procedures, blood tests, or stool samples that only provide snapshot information at specific points in time. This new research suggests that wearable devices might offer a far more convenient way to track disease activity.
“These findings open the door to leveraging wearable technology for health monitoring and disease management in innovative ways we haven’t previously considered,” said first author Dr. Robert Hirten, Clinical Director of the Hasso Plattner Institute for Digital Health, in a statement. Hirten is also an Associate Arofessor of Medicine (Gastroenterology), and Artificial Intelligence and Human Health, at the Icahn School of Medicine at Mount Sinai.
The IBD Forecast Study engaged 309 participants who wore either an Apple Watch, Fitbit, or Oura Ring while answering daily surveys about their symptoms. Researchers collected various physiological measurements, including heart rate, heart rate variability (HRV), daily steps, and blood oxygen levels. These metrics provide valuable insights into the body’s autonomic nervous system, which shows significant changes during IBD flares.
A particularly significant finding emerged regarding the body’s physiological signals before visible symptoms appear. Similar to environmental indicators that precede weather changes, these devices detected subtle alterations in heart patterns and other measurements weeks before patients experienced a flare-up. This early warning system could enable preemptive treatment adjustments, potentially preventing or reducing flare severity.
The devices demonstrated an impressive ability to distinguish between true inflammatory flares and symptom-only flares, a crucial distinction in IBD care. This differentiation capability could help healthcare providers make more informed treatment decisions and reduce unnecessary medical interventions.
Analysis revealed significant differences in heart rate variability patterns between periods of active disease and remission. During inflammatory flares, participants showed higher heart rates and lower daily step counts compared to periods of remission. These changes remained consistent across different types of wearable devices, suggesting broad applicability across various commercially available products.
The research particularly resonates with current healthcare preferences, as patients increasingly seek non-invasive, continuous monitoring options. Rather than depending solely on periodic clinic visits or invasive tests, patients might soon access real-time insights about their disease activity through devices they already own and use.
Researchers believe consumer-grade wearable devices might serve as sophisticated medical monitors for other chronic inflammatory conditions in the future. This convergence of consumer technology and medical care represents an emerging trend in healthcare, where everyday devices become valuable tools for disease management.
“Our study shows that commonly used wearable devices such as Apple Watches, Fitbits, and Oura Rings can be effective tools in monitoring chronic inflammatory diseases like IBD. This creates an opportunity to monitor the disease remotely outside the health care setting, in a continuous manner, and potentially in real time,” said Dr. Hirten. “Our hope is that, in the future, this approach will significantly enhance the quality of life of our patients.”
Paper Summary
Methodology
Researchers recruited participants nationwide through social media, study flyers, and email outreach to IBD patients at Mount Sinai Hospital. Participants used their own wearable devices or received one from the study team. They downloaded a custom app called ehive, which collected their daily survey responses about disease symptoms and connected to their wearable devices. The devices measured heart rate, heart rate variability, steps, and oxygen levels (in newer Apple Watches). Participants also reported their routine blood test and stool test results through the app. The study ran from December 2021 to June 2023, with participants wearing their devices for at least 8 hours daily.
Results
The study found that physiological measurements from wearable devices could detect both inflammatory flares (indicated by elevated inflammatory markers in tests) and symptomatic flares (based on patient-reported symptoms). Heart rate variability showed different patterns during flares versus remission periods. Heart rate and resting heart rate were higher during flares, while daily step counts were lower during inflammatory flares. The devices could also distinguish between purely symptomatic flares and those with underlying inflammation. Most remarkably, these changes were detectable up to 7 weeks before flares occurred.
Limitations
Several limitations exist in this research. The physiological measurements from wearable devices can be affected by factors other than IBD, such as other medical conditions or stress. The study relied on routine medical tests rather than scheduled evaluations, making it harder to pinpoint exactly when flares began. Additionally, there’s no standardized definition for what constitutes a symptomatic flare, which could affect how results were classified. The study population might not represent all IBD patients, as digital study participants often differ from the general patient population.
Discussion and Takeaways
This study demonstrates that common wearable devices could potentially transform IBD monitoring from periodic snapshots to continuous assessment. The ability to predict flares weeks in advance could allow for earlier intervention and better disease management. The non-invasive nature of this monitoring approach makes it particularly attractive for long-term use. The research also suggests that wearable devices might help distinguish between inflammatory and non-inflammatory flares, which could improve treatment decisions.
Funding and Disclosures
The study was supported by grant K23DK129835 (Robert P Hirten) and received generous support from Ms. Jenny Steingart. Several authors disclosed consulting relationships with pharmaceutical companies and medical technology firms. Dr. Hirten reported consulting for Bristol Meyers Squibb, while other authors reported various consulting relationships with pharmaceutical companies and equity ownership in health-related companies.
Publication Information
This research article, titled “Physiological Data Collected from Wearable Devices Identify and Predict Inflammatory Bowel Disease Flares,” was authored by researchers primarily affiliated with the Icahn School of Medicine at Mount Sinai in New York. The paper includes contributions from multiple departments, including Gastroenterology, Digital Health, Artificial Intelligence and Human Health, and Population Health Science and Policy.
